253 related articles for article (PubMed ID: 34442438)
1. ILB
Lazzarino G; Mangione R; Belli A; Di Pietro V; Nagy Z; Barnes NM; Bruce L; Ropero BM; Persson LI; Manca B; Saab MW; Amorini AM; Tavazzi B; Lazzarino G; Logan A
J Pers Med; 2021 Aug; 11(8):. PubMed ID: 34442438
[TBL] [Abstract][Full Text] [Related]
2. A phase II open label clinical study of the safety, tolerability and efficacy of ILB® for Amyotrophic Lateral Sclerosis.
Logan A; Nagy Z; Barnes NM; Belli A; Di Pietro V; Tavazzi B; Lazzarino G; Lazzarino G; Bruce L; Persson LI
PLoS One; 2022; 17(5):e0267183. PubMed ID: 35613082
[TBL] [Abstract][Full Text] [Related]
3. ILB
Lazzarino G; Di Pietro V; Rinaudo M; Nagy Z; Barnes NM; Bruce L; Signoretti S; Mangione R; Saab MW; Tavazzi B; Belli A; Lazzarino G; Amorini AM; Logan A
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955592
[TBL] [Abstract][Full Text] [Related]
4. Low Molecular Weight Dextran Sulfate (ILB
Lazzarino G; Amorini AM; Barnes NM; Bruce L; Mordente A; Lazzarino G; Pietro VD; Tavazzi B; Belli A; Logan A
Antioxidants (Basel); 2020 Sep; 9(9):. PubMed ID: 32927770
[TBL] [Abstract][Full Text] [Related]
5. The mechanism of action of a novel neuroprotective low molecular weight dextran sulphate: New platform therapy for neurodegenerative diseases like Amyotrophic Lateral Sclerosis.
Logan A; Belli A; Di Pietro V; Tavazzi B; Lazzarino G; Mangione R; Lazzarino G; Morano I; Qureshi O; Bruce L; Barnes NM; Nagy Z
Front Pharmacol; 2022; 13():983853. PubMed ID: 36110516
[No Abstract] [Full Text] [Related]
6. An Exploratory Trial of EPI-589 in Amyotrophic Lateral Sclerosis (EPIC-ALS): Protocol for a Multicenter, Open-Labeled, 24-Week, Single-Group Study.
Haji S; Fujita K; Oki R; Osaki Y; Miyamoto R; Morino H; Nagano S; Atsuta N; Kanazawa Y; Matsumoto Y; Arisawa A; Kawai H; Sato Y; Sakaguchi S; Yagi K; Hamatani T; Kagimura T; Yanagawa H; Mochizuki H; Doyu M; Sobue G; Harada M; Izumi Y
JMIR Res Protoc; 2023 Jan; 12():e42032. PubMed ID: 36716091
[TBL] [Abstract][Full Text] [Related]
7. Decreased Mitochondrial Function, Biogenesis, and Degradation in Peripheral Blood Mononuclear Cells from Amyotrophic Lateral Sclerosis Patients as a Potential Tool for Biomarker Research.
Araujo BG; Souza E Silva LF; de Barros Torresi JL; Siena A; Valerio BCO; Brito MD; Rosenstock TR
Mol Neurobiol; 2020 Dec; 57(12):5084-5102. PubMed ID: 32840822
[TBL] [Abstract][Full Text] [Related]
8. β-N-methylamino-l-alanine causes neurological and pathological phenotypes mimicking Amyotrophic Lateral Sclerosis (ALS): the first step towards an experimental model for sporadic ALS.
de Munck E; Muñoz-Sáez E; Miguel BG; Solas MT; Ojeda I; Martínez A; Gil C; Arahuetes RM
Environ Toxicol Pharmacol; 2013 Sep; 36(2):243-255. PubMed ID: 23688553
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis.
Zhao J; Wang X; Huo Z; Chen Y; Liu J; Zhao Z; Meng F; Su Q; Bao W; Zhang L; Wen S; Wang X; Liu H; Zhou S
Cells; 2022 Jun; 11(13):. PubMed ID: 35805131
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis.
Miquel E; Cassina A; Martínez-Palma L; Souza JM; Bolatto C; Rodríguez-Bottero S; Logan A; Smith RA; Murphy MP; Barbeito L; Radi R; Cassina P
Free Radic Biol Med; 2014 May; 70():204-13. PubMed ID: 24582549
[TBL] [Abstract][Full Text] [Related]
11. Serum N-acetylaspartate level in amyotrophic lateral sclerosis.
Simone IL; Ruggieri M; Tortelli R; Ceci E; D'Errico E; Leo A; Zoccolella S; Mastrapasqua M; Capozzo R; Livrea P; Logroscino G
Arch Neurol; 2011 Oct; 68(10):1308-12. PubMed ID: 21987545
[TBL] [Abstract][Full Text] [Related]
12. CNS glucose metabolism in Amyotrophic Lateral Sclerosis: a therapeutic target?
Tefera TW; Steyn FJ; Ngo ST; Borges K
Cell Biosci; 2021 Jan; 11(1):14. PubMed ID: 33431046
[TBL] [Abstract][Full Text] [Related]
13. Targeting Tau Mitigates Mitochondrial Fragmentation and Oxidative Stress in Amyotrophic Lateral Sclerosis.
Petrozziello T; Bordt EA; Mills AN; Kim SE; Sapp E; Devlin BA; Obeng-Marnu AA; Farhan SMK; Amaral AC; Dujardin S; Dooley PM; Henstridge C; Oakley DH; Neueder A; Hyman BT; Spires-Jones TL; Bilbo SD; Vakili K; Cudkowicz ME; Berry JD; DiFiglia M; Silva MC; Haggarty SJ; Sadri-Vakili G
Mol Neurobiol; 2022 Jan; 59(1):683-702. PubMed ID: 34757590
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial Dyshomeostasis as an Early Hallmark and a Therapeutic Target in Amyotrophic Lateral Sclerosis.
Belosludtseva NV; Matveeva LA; Belosludtsev KN
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069154
[TBL] [Abstract][Full Text] [Related]
15. Amyotrophic Lateral Sclerosis and Oxidative Stress: A Double-Blind Therapeutic Trial After Curcumin Supplementation.
Chico L; Ienco EC; Bisordi C; Lo Gerfo A; Petrozzi L; Petrucci A; Mancuso M; Siciliano G
CNS Neurol Disord Drug Targets; 2018; 17(10):767-779. PubMed ID: 30033879
[TBL] [Abstract][Full Text] [Related]
16. Treatment with Hydrogen-Rich Saline Delays Disease Progression in a Mouse Model of Amyotrophic Lateral Sclerosis.
Zhang Y; Li H; Yang C; Fan DF; Guo DZ; Hu HJ; Meng XE; Pan SY
Neurochem Res; 2016 Apr; 41(4):770-8. PubMed ID: 26537817
[TBL] [Abstract][Full Text] [Related]
17. Mitochondria: A Promising Convergent Target for the Treatment of Amyotrophic Lateral Sclerosis.
Cunha-Oliveira T; Montezinho L; Simões RF; Carvalho M; Ferreiro E; Silva FSG
Cells; 2024 Jan; 13(3):. PubMed ID: 38334639
[TBL] [Abstract][Full Text] [Related]
18. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.
Imamura K; Izumi Y; Banno H; Uozumi R; Morita S; Egawa N; Ayaki T; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Oki R; Fujita K; Takahashi N; Ikeda T; Shimizu A; Morinaga A; Hirohashi T; Fujii Y; Takahashi R; Inoue H
BMJ Open; 2019 Dec; 9(12):e033131. PubMed ID: 31796494
[TBL] [Abstract][Full Text] [Related]
19. Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS).
Mandrioli J; Crippa V; Cereda C; Bonetto V; Zucchi E; Gessani A; Ceroni M; Chio A; D'Amico R; Monsurrò MR; Riva N; Sabatelli M; Silani V; Simone IL; Sorarù G; Provenzani A; D'Agostino VG; Carra S; Poletti A
BMJ Open; 2019 May; 9(5):e028486. PubMed ID: 31152038
[TBL] [Abstract][Full Text] [Related]
20. Interplay between TDP-43 and docosahexaenoic acid-related processes in amyotrophic lateral sclerosis.
Cacabelos D; Ayala V; Granado-Serrano AB; Jové M; Torres P; Boada J; Cabré R; Ramírez-Núñez O; Gonzalo H; Soler-Cantero A; Serrano JC; Bellmunt MJ; Romero MP; Motilva MJ; Nonaka T; Hasegawa M; Ferrer I; Pamplona R; Portero-Otín M
Neurobiol Dis; 2016 Apr; 88():148-60. PubMed ID: 26805387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
